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Genome-wide association studies revealed that variants within FTO (fat-mass- and obesity-associated) are
strongly associated with obesity susceptibility. A recent study in Nature Genetics (Church et al., 2010)
demonstrates that mice overexpressing fto exhibit a dose-dependent increase in body weight, confirming
a role for FTO in the development of obesity.Evidence shows that the variance in body
mass index (BMI) within a population that
shares the same environment is strongly
genetically determined. Genome-wide
association studies (GWAS), conducted in
population-based cohorts assessed for
BMIor inobesecasesversusnormalweight
controls, have identified several genetic
regions where single-nucleotide polymor-
phisms (SNPs) are associated with an
increased risk of obesity. The strongest
association with BMI in Caucasians has
consistently been found with SNPs in the
first intron of a gene named fat-mass- and
obesity-associated gene (FTO) (Frayling
et al., 2007), an association replicated in
many population-based cohorts of adult-
and childhood-onset obesity and in several
different ethnic groups. Studies have
consistently demonstrated that carriers of
the most common obesity-associated risk
allele have an increased energy intake with
no evidence for an effect on energy expen-
diture (Cecil et al., 2008). Therefore, there
has been considerable interest in establish-
ing whether FTO or another gene in the
same locus is involved in energy homeo-
stasis. In a recent paper inNature Genetics,
Cox and colleagues provide a key piece of
evidence strengthening the candidacy of
the FTO gene product in the development
of obesity (Church et al., 2010).
FTO was previously found to be an
AlkB-like 2-oxoglutarate-dependent nu-
cleic acid demethylase (Gerken et al.,
2007). Resequencing studies have been
performed in large numbers of obese
and lean subjects, but heterozygous
loss-of-function mutations in FTO were
found at a comparable frequency in these
groups (Meyre et al., 2010). A rare homo-
zygous missense mutation in FTO that
inhibits catalytic activity was found in
a consanguineous family in association
with a complex severe polymalformationsyndrome and postnatal lethality, with no
obvious body weight phenotype (Boissel
et al., 2009).
In rodents, fto is widely expressed in
a number of regions important for energy
balance, including skeletal muscle, liver,
adipose tissue, and the brain, where
hypothalamic mRNA levels are influenced
by nutritional state (Gerken et al., 2007).
Knockdown of fto in the hypothalamic
arcuate nucleus of rats increased food
intake, while overexpression decreased
it (Tung et al., 2010). These effects were
not seen when fto was manipulated in the
paraventricular nucleus, suggesting that
effects may differ depending on the brain
region, tissue, and/or stage of develop-
ment. Mice lacking fto show increased
postnatal lethality, postnatal growth retar-
dation, reduced fat mass, increased
energy expenditure, and a relative increase
in food intake (Fischer et al., 2009).
In this study, Cox and colleagues
provide direct evidence for the role of
FTO in obesity by generating mice that
globally expressed either one or two
additional copies of the fto gene (Church
et al., 2010). FTO-3 and FTO-4 mice
(which had either three or four copies of
fto) displayed increased fto expression in
multiple tissues. Notably, there was wide
variation in tissue expression levels
compared to wild-type mice (FTO-2);
for example, fto mRNA was increased
8-fold in the pancreas in FTO-3 mice
and 11-fold in skeletal muscle in FTO-4
mice. Mice carrying additional copies of
the fto gene were obese, predominantly
due to an increase in fat mass. FTO-3
and FTO-4 mice had increased food
intake compared to FTO-2 mice. FTO-4
mice showed a significant increase in
energy expenditure on a standard diet,
but there were no differences in respira-
tory exchange ratio or locomotor activity.Cell MetabolismWhile hyperleptinemia is a robust and
reproducible feature of obesity in mice
and, indeed, humans, Church et al.
observed a reduction in circulating leptin
levels in male and female FTO-4 mice
compared to FTO-2 mice at 8 weeks.
This finding is intriguing and suggests
that fto overexpression may alter leptin
expression or secretion from adipose
tissue. It is plausible that these lower
leptin levels may contribute to the hyper-
phagia of FTO-3 and FTO-4 mice. Addi-
tional studies of the leptin response in
these mice will be of interest.
This study provides critical evidence to
support FTO as the gene underlying the
obesity association signal in several
GWASs. Another closely located gene,
RPGRIP1L (retinitis pigmentosa GTPase
regulator-interacting protein-1-like gene)
is a component of the basal body of
the primary cilium, but so far the balance
of evidence lies with FTO. The next
challenge is to determine a direct connec-
tion between genetic variants in the first
intron of the FTO gene and increased
expression of FTO, as the studies of
Church et al. suggest that a gain of func-
tion contributes to weight gain. A small
study of five individuals heterozygous for
the most common obesity-associated
SNP (rs9939609) found that FTO tran-
scripts containing the A (risk) allele were
more abundant than thosewith the T allele
in RNA preparations from blood and fibro-
blasts (Berulava and Horsthemke, 2010),
but further studies will be needed to
confirm these observations.
These studies pave the way for further
work on FTO, which, given its ubiquitous
expression in the embryo and adult
organism, will need to be studied in
models of tissue-specific overexpression,
possibly at different developmental
stages. One critical question is whether13, January 5, 2011 ª2011 Elsevier Inc. 7
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Previewsthe effects of FTO overexpression on
obesity are mediated via the brain or other
tissues. Deletion of fto in the brain recapit-
ulates the reduced bodyweight of fto nulls,
indicating that central mechanisms are
likely to play a major role (Gao et al., 2010).
Finally, studies of the FTO association
signal have taught us that understanding
the biology underlying these genetic
associations can be a complex and chal-
lenging task. As more common variants
and, indeed, rare variants emerge from
hypothesis-free genetic approaches,
collaborative work across disciplines will
be needed to link these genes to physio-
logical and pathophysiological processes
and thus to explore their utility as potential
molecular targets for intervention in8 Cell Metabolism 13, January 5, 2011 ª2011patients with obesity and associated
metabolic diseases.REFERENCES
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PLoS ONE 5, e8771.The Tumor Suppressor LKB1 Emerges
as a Critical Factor in Hematopoietic
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Howcellularmetabolism regulates stem cell function is poorly understood but is an emerging field of study. In
a recent issue of Nature, three independent groups demonstrate that LKB1 promotes hematopoietic stem
cell (HSC) quiescence and metabolic homeostasis. Surprisingly, these effects on HSCs occur independently
of AMPK/mTOR and FoxO signaling.LKB1 is a tumor suppressor that is inacti-
vated in the Peutz-Jeghers familial cancer
syndrome. Best characterized as a serine/
threonine kinase acting upstream of
the adenine monophosphate-activated
protein kinase (AMPK) and mammalian
target of rapamycin (mTOR) pathways,
LKB1 is currently viewed as a master
regulator of cellular metabolism that
restricts cell growth under energetically
unfavorable conditions (Shackelford and
Shaw, 2009). Increased cellular AMP/
ATP ratios result in enhanced AMPK
phosphorylation and activation by LKB1.Activated AMPK in turn phosphory-
lates the tuberous sclerosis complex
(TSC), which inhibits mTOR complex 1
(mTORC1), resulting in reduced mRNA
translation and cell growth. LKB1 also
modulates metabolism via other AMPK
targets (such as the FoxO transcription
factors) or additional substrates, like the
14 AMPK-related kinases. Although the
role of LKB1 in regulating metabolic
activity in cancer is well established,
its impact on stem cells has yet to be
fully explored. Accordingly, three recent
reports in Nature (Gan et al., 2010; Guru-murthy et al., 2010; Nakada et al., 2010)
demonstrate that LKB1 plays a critical
role in hematopoietic stem cell (HSC)
quiescence.
The hematopoietic system functions to
replenish multilineage blood cells from
early embryonic development throughout
adulthood. Multipotent HSCs give rise to
all mature blood lineages and must main-
tain a delicate balance between quies-
cence, self-renewal, and differentiation.
Complex regulatory mechanisms, both
cell intrinsic and cell extrinsic, modulate
this balance and have profound influence
